The Egyptian Journal of Internal Medicine

ORIGINAL ARTICLE
Year
: 2014  |  Volume : 26  |  Issue : 1  |  Page : 6--14

Impact of hepcidin, interleukin 6, and other inflammatory markers with respect to erythropoietin on anemia in chronic hemodialysis patients


Ihab A. Ibrahim1, Usama M. Mohamad1, Hatem A. Darweesh1, Amal M. Rashad2 
1 Department of Internal Medicine, Division of Nephrology, Cairo University, Cairo, Egypt
2 Department of Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt

Correspondence Address:
Ihab A. Ibrahim
BSc, MD, Departments of Internal Medicine, Division of Nephrology, Faculty of Medicine, Cairo University, 12918 Cairo
Egypt

Background/objective Hepcidin is a peptide hormone produced by the liver and appears to be the master regulator of iron homeostasis. This peptide is upregulated in inflammatory conditions, including uremia. Hepcidin functions to regulate (inhibit) iron transport across the gut mucosa, thereby preventing excess iron absorption and maintaining normal iron levels within the body. In this study, we aimed to investigate hepcidin levels and their relationship with the parameters of iron status, inflammation, anemia therapy, and parameters of dialysis efficiency in hemodialysis patients. Patients and methods Plasma hepcidin-25, inflammatory markers (high-sensitivity C-reactive protein and interleukin 6), and peripheral iron indices (serum iron, total iron-binding capacity, transferrin saturation and serum ferritin) were measured before hemodialysis in 40 end-stage renal disease (ESRD) patients treated with regular hemodialysis in a single dialysis unit as well as in 20 healthy individuals matched for age and sex serving as the control group. Results Plasma levels of hepcidin-25 were significantly higher in hemodialysis patients compared with controls. In a simple correlation analysis, plasma hepcidin levels were positively correlated with ferritin, transferrin saturation, CRP, and interleukin 6; however, it was negatively correlated with hemoglobin, dose of epoitin-α, and dose of iron. Conclusion Serum hepcidin levels were associated with iron status and inflammation in maintenance hemodialysis patients, and the high hepcidin serum levels, found in hemodialysis (HD) patients, are dependent on the magnitude of the inflammatory process and on recombinant human erythropoietin doses. Hepcidin and its regulatory pathways are potential therapeutic targets, which could lead to effective treatment of anemia in chronic hemodialysis.


How to cite this article:
Ibrahim IA, Mohamad UM, Darweesh HA, Rashad AM. Impact of hepcidin, interleukin 6, and other inflammatory markers with respect to erythropoietin on anemia in chronic hemodialysis patients.Egypt J Intern Med 2014;26:6-14


How to cite this URL:
Ibrahim IA, Mohamad UM, Darweesh HA, Rashad AM. Impact of hepcidin, interleukin 6, and other inflammatory markers with respect to erythropoietin on anemia in chronic hemodialysis patients. Egypt J Intern Med [serial online] 2014 [cited 2019 Sep 21 ];26:6-14
Available from: http://www.esim.eg.net/article.asp?issn=1110-7782;year=2014;volume=26;issue=1;spage=6;epage=14;aulast=Ibrahim;type=0